Skip to main content
Back
SBHMY logo

Sino Biopharmaceutical Limited

Data quality: 100%
Oversold
SBHMY
OTC Healthcare Biotechnology
$15.89
$0.00 (0.00%)
Mkt Cap: 14.21B
Also listed as SBMFF OTC
Day Range
$15.89 $17.65
52-Week Range
$8.76 $20.16
Volume
100
50D / 200D Avg
$16.44 / $17.55
Prev Close
$15.89

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 4.1 0.4
P/B 0.4 2.9
ROE % 11.2 3.8
Net Margin % 12.1 3.9
Rev Growth 5Y % 5.1 10.0
D/E 0.3 0.2

Key Takeaways

Revenue grew 5.11% annually over 5 years — modest growth
Earnings grew 50.08% over the past year
ROE of 11.21% — decent returns on equity
Debt/Equity of 0.31 — conservative balance sheet
Generating 5.22B in free cash flow
P/E of 4.06 — trading at a low valuation

Growth

Revenue Growth (5Y)
5.11%
Revenue (1Y)10.18%
Earnings (1Y)50.08%
FCF Growth (3Y)7.01%

Quality

Return on Equity
11.21%
ROIC11.02%
Net Margin12.12%
Op. Margin21.26%

Safety

Debt / Equity
0.31
Current Ratio1.26
Interest Coverage20.79

Valuation

P/E Ratio
4.06
P/B Ratio0.44
EV/EBITDA2.35
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.18% Revenue Growth (3Y) 5.31%
Earnings Growth (1Y) 50.08% Earnings Growth (3Y) 17.30%
Revenue Growth (5Y) 5.11% Earnings Growth (5Y) 6.01%
Profitability
Revenue (TTM) 28.87B Net Income (TTM) 3.50B
ROE 11.21% ROA 5.35%
Gross Margin 81.51% Operating Margin 21.26%
Net Margin 12.12% Free Cash Flow (TTM) 5.22B
ROIC 11.02% FCF Growth (3Y) 7.01%
Safety
Debt / Equity 0.31 Current Ratio 1.26
Interest Coverage 20.79 Dividend Yield 0.04%
Valuation
P/E Ratio 4.06 P/B Ratio 0.44
P/S Ratio 0.49 PEG Ratio 0.10
EV/EBITDA 2.35 Dividend Yield 0.04%
Market Cap 14.21B Enterprise Value 14.42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 28.87B 26.20B 26.03B 26.86B 23.65B
Net Income 3.50B 2.33B 2.54B 14.61B 2.77B
EPS (Diluted) 3.80 1.99 2.40 14.60 3.00
Gross Profit 23.53B 21.21B 21.54B 21.53B 18.46B
Operating Income 6.14B 5.79B 5.59B 5.08B 4.19B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 65.41B 63.60B 64.06B 60.54B 47.21B
Total Liabilities 22.63B 25.43B 26.12B 22.81B 24.79B
Shareholders' Equity 31.96B 30.47B 29.75B 30.29B 16.75B
Total Debt 9.78B 12.58B 13.98B 12.12B 14.21B
Cash & Equivalents 9.57B 9.45B 8.65B 9.60B 10.62B
Current Assets 24.69B 23.81B 25.93B 23.50B 22.79B
Current Liabilities 19.56B 22.61B 20.15B 15.35B 10.94B

Strategy Scores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#161 of 1024
64
Custom Deep Value Investing (Seth Klarman)
#3 of 820
88
Value Defensive Investing (Benjamin Graham)
#7 of 708
82

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026